AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Cash Discounts Charged Against Gross Revenues by Year
Cash Discounts Charged Against Gross Revenues ($B)
AbbVie Cash Discounts Charged Against Gross Revenues: $2.20B in FY2025, up 10.0% from a year earlier.
Latest, FY2025
2.20
Period ended Dec 31, 2025
Change on a year earlier
+10.0%
2.00 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“Cash discounts totaled $2.2 billion in 2025, $2.0 billion in 2024 and $2.0 billion in 2023.”
Source: Form 10-K (abbv-20251231.htm, filed 2026-02-20) ↗
Reported in Form 10-K Item 7 MD&A Gross Margin & Rebates Rollforward.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash Discounts Charged Against Gross Revenues ($B) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.20 | +10.0% | Form 10-K (abbv-20251231.htm, filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 2.00 | 0.0% | Form 10-K (abbv-20251231.htm, filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 2.00 | +11.1% | Form 10-K (abbv-20251231.htm, filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 1.80 | +12.5% | Form 10-K (abbv-20241231.htm, filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1.60 | +33.3% | Form 10-K (abbv-20231231.htm, filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 1.20 | – | Form 10-K (abbv-20221231.htm, filed 2023-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Cash Discounts Charged Against Gross Revenues, annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/gtn-cash-disc-b
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.